FibroBiologics(FBLG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FBLG FibroBiologics

Pre-Mkt 12-18 04:34:48 EST

0.2758

+0.0350

+14.53%

High0.2860	Low0.2405	Vol2.26M
Open0.2460	D1 Closing0.2408	Amplitude18.90%
Mkt Cap18.35M	Tradable Cap15.60M	Total Shares66.52M
T/O594.04K	T/O Rate4.00%	Tradable Shares56.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":0.2758,"timestamp":1766005200000,"preClose":0.2408,"halted":0,"volume":2262874,"delay":0,"floatShares":56556500,"shares":66519700,"eps":-0.484982,"marketStatus":"Pre-Mkt","change":0.035,"latestTime":"12-18 04:34:48 EST","open":0.246,"high":0.286,"low":0.2405,"amount":594036.82935568,"amplitude":0.188953,"askPrice":0.323,"askSize":100,"bidPrice":0.25,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.484982,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":0.2758,"postHourTrading":{"tag":"盘后","latestPrice":0.2743,"preClose":0.2758,"latestTime":"19:55 EST","volume":26441,"amount":7203.3324,"timestamp":1766019310022},"volumeRatio":0.7419084363923031},"requestUrl":"/m/hq/s/FBLG/wiki","defaultTab":"wiki","newsList":[{"id":"2591649631","title":"Fibrobiologics Announces $1.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649631?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUABXDLM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2591499596","title":"Press Release: FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2591499596","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591499596?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803600,"startTime":"0","endTime":"0","summary":"HOUSTON, Dec. 15, 2025  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 5,227,275 shares of its common stock at an offering price of $0.33 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 5,227,275 shares of common stock at an exercise price of $0.33 per share. The unregistered warrants will be exercisable beginning on the effective date of, and subject to, approval by the Company's stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrants  and will expire five years followi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139","NQmain"],"gpt_icon":0},{"id":"2590505734","title":"Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505734","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505734?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:16","pubTimestamp":1765541802,"startTime":"0","endTime":"0","summary":"Ruben A. Garcia, General Counsel of Fibrobiologics Inc., has reported the acquisition of common shares of the company, according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL8NqByT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2590580765","title":"FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2590580765","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590580765?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373400,"startTime":"0","endTime":"0","summary":"Platform Poised to Expand into Joint and Cartilage RepairHOUSTON, Dec.  10, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechn","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203156/0/en/FibroBiologics-Files-Patent-Application-Covering-Novel-Fibroblast-Based-Chondrocyte-Spheroid-Platform-for-Orthopedic-and-Musculoskeletal-Conditions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586250210","title":"FibroBiologics announces payoff of outstanding debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250210","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250210?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:40","pubTimestamp":1764164432,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) has paid all amounts outstanding under the convertible promissory notes issued to YA II PN, pursuant to the Standby Equity Pu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-announces-payoff-of-outstanding-debt-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-announces-payoff-of-outstanding-debt-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586257443","title":"Fibrobiologics Announces Payoff of Outstanding Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257443?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X2056:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586257402","title":"Fibrobiologics Inc - Pays off All  Amounts Outstanding  Under Convertible Notes Issued to Ya Ii Pn, Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X2056:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586257428","title":"FibroBiologics Repays All Outstanding Convertible Debt, Eliminates Further Dilution","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257428","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257428?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163810,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. has announced that it has fully repaid all outstanding amounts under its convertible promissory notes previously issued to YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global. The repayment eliminates further dilution from potential conversions of these notes into common stock. With the debt now cleared, FibroBiologics' balance sheet is strengthened, allowing the company to focus on advancing its clinical programs. The Standby Equity Purchase Agreement with Yorkville remains in place, permitting the company to sell up to an additional $10 million of its common stock at its discretion through December 2026, subject to certain conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5jn93m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","FBLG","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2586340402","title":"BRIEF-Fibrobiologics Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2586340402","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586340402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:34","pubTimestamp":1764110058,"startTime":"0","endTime":"0","summary":"BRIEF-Fibrobiologics Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNov 25 (Reuters) - Fibrobiologics Inc FBLG.O:FIBROBIOLOGICS ANNOUNCES CLOSING O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUAB96WF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586404576","title":"FibroBiologics Closes $1.5 Million Registered Direct Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2586404576","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586404576?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:14","pubTimestamp":1764108873,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) closed a registered direct offering of 4.48 million shares at $0.335 apiece, along with related warrants, for gross proceeds of $1.5 million.Net proceeds will be used for working capital and general corporate purposes, the company said Tuesday in a statement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2586093684","title":"FibroBiologics Raises $1.5 Million in Private Placement of Unregistered Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2586093684","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586093684?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:05","pubTimestamp":1764104724,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. announced the closing of a private placement in which it issued unregistered warrants to purchase up to 4,477,614 shares of common stock at an exercise price of $0.335 per share. These warrants were sold concurrently with a registered direct offering and will become exercisable following stockholder approval. If fully exercised, the warrants could provide the company with approximately $1.5 million in additional gross proceeds. The shares issuable upon exercise of the warrants have not been registered under the Securities Act and may not be sold in the United States without registration or an applicable exemption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL91vd3h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","FBLG"],"gpt_icon":0},{"id":"2586060454","title":"Fibrobiologics Announces Closing of $1.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2586060454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586060454?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:05","pubTimestamp":1764104700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUAB96WF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586209476","title":"FibroBiologics Announces Securities Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2586209476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586209476?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:59","pubTimestamp":1764079167,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. ( ($FBLG) ) just unveiled an announcement. On November 24, 2025, FibroBiologics, Inc. announced it entered into a securities p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-announces-securities-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-announces-securities-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2585460250","title":"FibroBiologics prices 4.48M shares at 33.5c in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460250","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585460250?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:10","pubTimestamp":1763993446,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) entered into definitive agreements for the issuance and sale of an aggregate of 4,477,614 shares of its common stock at an of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-prices-4-48m-shares-at-33-5c-in-registered-direct-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-prices-4-48m-shares-at-33-5c-in-registered-direct-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2585746059","title":"FibroBiologics Announces Private Placement of Unregistered Warrants for $1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2585746059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585746059?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:04","pubTimestamp":1763993071,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. has announced a private placement involving the issuance and sale of unregistered warrants to purchase up to 4,477,614 shares of common stock at an exercise price of $0.335 per share. The warrants, issued alongside a registered direct offering, will be exercisable upon stockholder approval and will expire five years after such approval is obtained. The unregistered warrants and the shares issuable upon exercise are being offered in a private placement under Section 4 of the Securities Act and/or Regulation D, and have not been registered under the Act or applicable state securities laws. The company expects potential gross proceeds of approximately $1.5 million from the warrants if fully exercised, in addition to the proceeds from the registered offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLb6r0j7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2585605644","title":"Fibrobiologics Inc - to Issue 4,477,614 Shares of Common Stock at $0.335 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2585605644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585605644?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:00","pubTimestamp":1763992804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA4FKQ7C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2585460931","title":"FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460931","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585460931?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:00","pubTimestamp":1763992800,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov.  24, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193572/0/en/FibroBiologics-Announces-1-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","NQmain","QLD","FBLG","NVIW.SI","BK4139","TSYW.SI","QID","USJW.SI",".IXIC","PSQ","USAW.SI","MNQmain","TQQQ"],"gpt_icon":1},{"id":"2584213442","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584213442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584213442?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:18","pubTimestamp":1763644680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 08:18 ET (13:18 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2584131288","title":"Fibrobiologics Receives Hrec Approval for Phase 1/2 Clinical Trial for Cywc628 for the Treatment of Refractory Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2584131288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584131288?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:00","pubTimestamp":1763643605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA9PJXVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2584131071","title":"FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2584131071","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584131071?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:00","pubTimestamp":1763643600,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov.  20, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the dev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191847/0/en/FibroBiologics-Receives-HREC-Approval-for-Phase-1-2-Clinical-Trial-for-CYWC628-for-the-Treatment-of-Refractory-Diabetic-Foot-Ulcers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","FBLG","BK4139","TGA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fibrobiologics.com","stockEarnings":[{"period":"1week","weight":-0.1685},{"period":"1month","weight":-0.1767},{"period":"3month","weight":-0.4845},{"period":"6month","weight":-0.6035},{"period":"1year","weight":-0.8717},{"period":"ytd","weight":-0.8621}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","exchange":"NASDAQ","name":"FibroBiologics","nameEN":"FibroBiologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FibroBiologics(FBLG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest FibroBiologics(FBLG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"FibroBiologics,FBLG,FibroBiologics股票,FibroBiologics股票老虎,FibroBiologics股票老虎国际,FibroBiologics行情,FibroBiologics股票行情,FibroBiologics股价,FibroBiologics股市,FibroBiologics股票价格,FibroBiologics股票交易,FibroBiologics股票购买,FibroBiologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FibroBiologics(FBLG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest FibroBiologics(FBLG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}